clinical trial · NCT03862807
Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Disease Progression Post-Liver Transplant
Amyloidosis, FamilialTransthyretin AmyloidosisPatisiran
brief summary
The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of patisiran in participants with hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) with disease progression after liver transplant.
started
Mar 27, 2019
primary completion
Oct 6, 2020
completion
Oct 20, 2020
last updated
Apr 22, 2024
official title
An Open-label Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of Patisiran-LNP in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) With Disease Progression Post-Orthotopic Liver Transplant
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol